Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald F Watts

Showing results (11-20 of 705) with videos related to

Pageof 71
Sort By:
Heart (British Cardiac Society)|February 8, 2011
Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patientGerald F Watts, Fredrik Karpe
Atherosclerosis. Supplements|May 14, 2010
Progress in understanding postprandial dyslipidaemia: Second International Symposium on the Role of Chylomicrons in Disease lGerald F Watts, Josep Ribalta
Current Vascular Pharmacology|December 28, 2019
Familial Hypercholesterolaemia Registry in the MENA RegionGenovefa Kolovou, Gerald F Watts
Current Vascular Pharmacology|January 18, 2019
Editorial: Familial Hypercholesterolaemia Registry in the MENA RegionGenovefa Kolovou, Gerald F Watts
European Heart Journal|January 15, 2017
ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?Gerald F Watts, Claudia Stefanutti
Atherosclerosis|May 12, 2026
Reply to "Reconsidering the role of liver transplantation in homozygous familial hypercholesterolaemia: beyond last-resort therapy"Jing Pang, Gerald F Watts
Cardiovascular Drugs and Therapy|August 6, 2013
New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?Amirhossein Sahebkar, Gerald F Watts
Current Opinion in Lipidology|March 10, 2016
Developing role of microRNA-33 in lipid metabolism and atherosclerosisAmirhossein Sahebkar, Gerald F Watts
Expert Review of Clinical Pharmacology|June 6, 2015
Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?Amirhossein Sahebkar, Gerald F Watts
International Journal of Cardiology|June 12, 2018
Squaring up the health economics of PCSK9 monoclonal antibodies 'down under'Gerald F Watts, Richard Norman
Pageof 71

Showing results (11-20 of 705) with videos related to

Sort By:
Pageof 71
Heart (British Cardiac Society)|February 8, 2011
Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patientGerald F Watts, Fredrik Karpe
Atherosclerosis. Supplements|May 14, 2010
Progress in understanding postprandial dyslipidaemia: Second International Symposium on the Role of Chylomicrons in Disease lGerald F Watts, Josep Ribalta
Current Vascular Pharmacology|December 28, 2019
Familial Hypercholesterolaemia Registry in the MENA RegionGenovefa Kolovou, Gerald F Watts
Current Vascular Pharmacology|January 18, 2019
Editorial: Familial Hypercholesterolaemia Registry in the MENA RegionGenovefa Kolovou, Gerald F Watts
European Heart Journal|January 15, 2017
ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?Gerald F Watts, Claudia Stefanutti
Atherosclerosis|May 12, 2026
Reply to "Reconsidering the role of liver transplantation in homozygous familial hypercholesterolaemia: beyond last-resort therapy"Jing Pang, Gerald F Watts
Cardiovascular Drugs and Therapy|August 6, 2013
New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?Amirhossein Sahebkar, Gerald F Watts
Current Opinion in Lipidology|March 10, 2016
Developing role of microRNA-33 in lipid metabolism and atherosclerosisAmirhossein Sahebkar, Gerald F Watts
Expert Review of Clinical Pharmacology|June 6, 2015
Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?Amirhossein Sahebkar, Gerald F Watts
International Journal of Cardiology|June 12, 2018
Squaring up the health economics of PCSK9 monoclonal antibodies 'down under'Gerald F Watts, Richard Norman
Pageof 71